DuPont has acquired another company—targeting the healthcare sector!

In June 2022, DuPont officially opened its Liveo medical-grade silicone adhesive manufacturing facility in South Carolina, USA. In the same month, DuPont announced plans to expand its production capacity for silicone materials used in biopharmaceutical applications in China. In August 2023, DuPont completed the acquisition of Spectrum Plastics Group for $1.75 billion. Spectrum’s business partially overlapped with that of Donatelle Plastics, and it specialized in specialty medical devices and components—spanning structural heart disease, electrophysiology, surgical robotics, and cardiovascular applications. Donatelle Plastics, with nearly 60 years of history and over 400 employees, holds strong financial growth potential across fields including electrophysiology, drug delivery, diagnostics, cardiac rhythm management, neuromodulation, and orthopedics. This strategic acquisition aims to further expand DuPont’s market presence in the medical device sector—signaling top management’s strong confidence in the industry’s growth trajectory and underscoring its high regard for the future prospects of upstream medical device markets. DuPont intends to deepen its footprint through strategic transformation and expansion. By broadening its scope in the medical device sector, DuPont is poised to enhance its competitiveness in the healthcare market and challenge the positions of current industry leaders. ▍A Century-Old Company Reclaiming Its Glory Over the past five years, DuPont has undergone two major spin-offs and multiple rounds of business restructuring to proactively respond to global economic uncertainty and fragility. While divesting legacy businesses—including its Transportation & Materials segment—it has continuously strengthened its competitive advantages and product portfolios in medical materials, electronic materials, and water treatment. In Q1 2024, DuPont reported net sales of $2.9 billion and operating EBITDA (earnings before interest, taxes, depreciation, and amortization) of $682 million. Driven by optimism regarding the sustained recovery of the electronics market—and industrial end-markets such as water treatment and medical packaging—DuPont raised its full-year financial guidance for net sales, operating EBITDA, and adjusted earnings per share, forecasting sequential improvement in both sales and profitability. In May this year, DuPont announced its formal split into three independent, publicly traded companies: New DuPont (comprising most of the Industrial Solutions segment—including healthcare—Water & Protection, and retained existing businesses), Electronics, and Water. See related article: “Doubling Down on Healthcare! Global Chemical Giant DuPont Splits Again.” New DuPont will assume responsibility for the global healthcare end-market, offering products and services spanning biopharmaceutical consumables, medical devices, and medical packaging. New DuPont’s projected 2023 revenue stands at approximately $6.6 billion, with an operating EBITDA margin of 24%. Its business is primarily distributed across healthcare, mobility, and safety & protection—including iconic brands such as Tyvek® and Kevlar®. In healthcare, key new offerings include a newly formulated Tyvek® medical packaging material—a high-density polyethylene fiber-based nonwoven technological material—as well as Liveo® flexible skin-conductive silicone tape, a thermosetting silicone adhesive designed for electrophysiological signal sensing and transmission. The spin-offs and restructuring efforts are beginning to yield tangible results. In Q2 2024, the company reported net sales of $3.2 billion—a 2% year-on-year increase, or 4% growth attributable to acquisitions.

Why is DuPont under investigation?

China’s antitrust investigation into DuPont reflects, in essence, the country’s broader efforts in recent years to strengthen market regulation and safeguard fair competition. This move stems not only from the need to regulate the market conduct of multinational corporations but also from China’s strategic considerations amid the ongoing global industrial chain reconfiguration. About DuPont: DuPont de Nemours, Inc. is a global chemical giant rooted in scientific innovation, with operations spanning high-performance materials, electronics & industrial solutions, and healthcare. It serves as an ‘invisible champion’ in critical sectors such as semiconductors, automotive, and new energy. In 2024, DuPont was ranked the world’s strongest chemical brand, achieving a Brand Strength Index (BSI) of 84.5—surpassing competitors including BASF and Dow Chemical. Its projected full-year 2024 net sales stand at $12.25 billion, with the Electronics & Industrial segment contributing 48% and the Healthcare segment accounting for 22%. High-Performance Materials: DuPont holds globally leading technologies in polyimide films, photoresists, and engineering plastics. • Kevlar®: Used in bulletproof vests and aerospace applications—global market share exceeds 70%; • Teflon®: Non-stick coating technology—dominates global cookware and industrial equipment markets; • Tyvek®: Medical protective and packaging material—holds an 80% market share in China; • Semiconductor Materials: Photoresists (15% global share), CMP polishing pads (79% global share), etc.—directly impacting chip manufacturing supply chains. Electronics & Industrial: • Structural adhesives and thermal interface materials: Hold over 60% market share in China’s battery and chip manufacturing sectors; • Display materials: Applied in high-end display technologies such as OLED—with over 30% global market share. Environmental Sustainability & Green Transition: Water treatment technologies (world-leading market share in reverse osmosis membranes); bio-based materials (PDO technology accounts for 90% of global production capacity)—supporting energy transition and carbon neutrality goals. Healthcare: Produces biopharmaceutical tubing (Liveo™), medical-grade silicone elastomers, etc. In 2024, DuPont inaugurated a new healthcare-focused manufacturing base in Zhangjiagang, China, dedicated to serving local biopharmaceutical customers. I. Direct Trigger of the Antitrust Investigation: Abuse of Dominant Market Position According to the State Administration for Market Regulation (SAMR), DuPont (China) Co., Ltd. has been formally investigated for suspected violations of the People’s Republic of China Anti-Monopoly Law. Industry analysis suggests that DuPont’s conduct in the high-performance materials sector may have crossed antitrust red lines: 1. Potential Risks of Horizontal Monopoly Agreements In niche markets such as specialty plastics and electronic chemicals, DuPont competes long-term with international chemical giants including Dow Chemical and BASF. The investigation may probe whether these firms engaged in collusive practices—such as price-fixing or market allocation. For example, in 2018, the European Commission fined four chemical companies €430 million for reaching a price-fixing agreement in the organic peroxides market. Also relevant is the so-called 'patent troll' behavior—for instance, the **Tyvek® material monopoly**: since its invention in 1955, this nonwoven material held a 58-year market monopoly; today, it commands an 80% market share in China. DuPont has filed patent infringement lawsuits against domestic Chinese enterprises—for example, suing a Chinese firm in 2024—but that firm has already achieved breakthroughs in independent process development.

DuPont raises full-year profit forecasts on strong healthcare, aerospace demand

6 hours ago

DuPont raised its full-year profit forecasts and Q4 earnings projections, beating Wall Street estimates driven by strong demand in healthcare, aerospace, and industrial water markets. It also surpassed third-quarter earnings expectations and expanded share buybacks.

Reuters

2026-05-05

DuPont Expected to Benefit from Long-Term Demand Growth in Healthcare and Water Filtration

2026-06-12

DuPont de Nemours Inc. Cash Flow Data for Argentina Operations

2026-06-24

DuPont Expected to Benefit from Long-Term Growth in Healthcare and Water Filtration

2026-06-27

DuPont de Nemours Inc (HAM:6D8) Stock Price & 30 Year Financial Data

2026-06-27

DuPont de Nemours Inc. Financial Actuals & Estimates